NANourhane Al Akoum

Nourhane Al Akoum

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Nourhane Al Akoum has a total of 53 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Alteration of macrophage infiltrates in the tumor immune microenvironment following Janus kinase 1 (JAK) inhibition: analysis from a prospective clinical trial in Leiomyosarcoma

    by Michael J. Wagner, Lee D. Cranmer, Elizabeth T. Loggers, Roxanne Moore, Hannah R. Abrams, Shannon Hill, Anirudh Goyal, Munther Baroudi, Niall Morin, Juliana Chi Kei Ng, et al.

  • Open Access

    Revisiting the Immune Frontier in Soft Tissue Sarcomas

    by Nadeem Bilani, Nourhane Al Akoum, Rusul Al-Marayaty, Sarah Orlando, Borislav Alexiev, Pedro Hermida de Viveiros, Seth M. Pollack

    Purpose of Review: Soft tissue sarcomas (STS) comprise a heterogeneous group of mesenchymal malignancies with limited treatment options and poor outcomes in the advanced setting. Although immune checkpoint inhibitors have transformed the management of many solid tumors, their efficacy in STS has been modest and strongly histology dependent. This review aims to synthesize recent advances in immuno-oncology as applied to STS and to highlight emerging strategies that may overcome resistance and improve patient outcomes. Recent Findings: Thus far, clinically meaningful activity of immune checkpoint inhibitors has been identified select STS subtypes, including undifferentiated pleomorphic sarcoma, angiosarcoma, and alveolar soft part sarcoma. Combination approaches incorporating immune checkpoint inhibitors with chemotherapy, radiation, tyrosine kinase inhibitors, or novel immune modulators have shown enhanced antitumor activity in early-phase and randomized trials. In parallel, engineered T-cell therapies targeting cancer-testis antigens have emerged as a standard-of-care option in synovial sarcoma and are being expanded to other histologies. Finally, advances in tumor microenvironment characterization, including the role of tertiary lymphoid structures and myeloid modulation, are refining patient selection and informing rational trial design. Summary: Immunotherapy continues to reshape the therapeutic landscape of soft tissue sarcoma. While immune checkpoint blockade alone benefits only a subset of patients, rational combination strategies and cellular therapies offer promising avenues to broaden clinical efficacy. Continued integration of biomarker-driven approaches, translational correlative studies, and histology-specific trial designs will be essential to fully realize the potential of immunotherapy in STS.


  • Open Access

    Future Directions and Priorities for Cellular Therapy in Sarcoma: A Report from the Strategic Advances in Sarcoma Science Cell Therapy Breakout

    by Jacqueline Oliva-Ramirez, David Milewski, Lauren Banks, Kelly M. Bailey, Everett J. Moding, Jessica Lake, Alice Chen, Jessica D. Daley, Erin E. Resch, Rosandra N. Kaplan, et al.

    Background: In September of 2024, the 2nd annual meeting of the Strategic Advances in Sarcoma Science (SASS) convened at the National Institutes of Health. This gathering of national sarcoma experts focused on preclinical studies, clinical trials, opportunities, challenges, and future directions in sarcoma biology and clinical care with a focus on immunotherapy. The Immunology in Sarcoma breakout group conducted a dedicated discussion focused on the current and future implementation of adoptive cellular therapies (ACTs) in sarcomas. The current manuscript summarizes these discussions and provides a comprehensive resource for researchers and clinicians. Results: Adoptive cell therapy (ACT) has shown encouraging results in sarcomas with afami-cel achieving durable responses in synovial sarcoma and early TCR-T trials against NY-ESO-1 and MAGE-A4 demonstrating meaningful response rates. Building on these outcomes will require discovering new targets, selecting optimal cell types, refining conditioning regimens, combining with alternative treatment strategies such as TKIs, and leveraging predictive biomarkers informed by a deeper understanding of the tumor microenvironment. Conclusions: Sarcomas are promising targets for adoptive cell therapy (ACT), as shown by afami-cel’s success in synovial sarcoma, but broader impact requires new target discovery, optimal cell selection, improved conditioning, combination treatments, deeper tumor microenvironment understanding, and predictive biomarkers to achieve more durable responses for more patients.


  • Open Access

    A minireview of cholera outbreak in Lebanon – a rising public health concern

    by Christin Berjaoui, Nourhane Al Akoum, Ahmad El Nouiri, Saadeddine Khayat, Mortada Abbass, AlHareth Al Mousawi, Jack Wellington, Olivier Uwishema

    Cholera is a highly contagious illness that can cause severe acute watery diarrhoea. The World Health Organisation (WHO) and the Lebanese Ministry of Health announced on the 10th of October 2022 the re-emergence of Cholera in Lebanon. Data was collected from the Ministry of Public Health in Lebanon, World Health Organization, news announcements, as well as from online databases such as PubMed, Science Direct, news, conferences and press releases on the current cholera outbreak. More than 669 cholera confirmed cases and 23 deaths have been reported in Lebanon up till December 29, 2022. The Ministry of Public Health is providing cooperation and support in containing the disease, and covering the hospital and treatment expenses for cholera patients. This paper aims to study the epidemiology of cholera, focusing on the most recent cholera outbreak in Lebanon, and to suggest some recommendations which can be followed to fight off this outbreak.